Amedisys (AMED) Misses Q3 EPS by 10c

Amedisys (NASDAQ: AMED) reported Q3 EPS of $0.98, $0.10 worse than the analyst estimate of $1.08. Revenue for the quarter came in at $556.24 million versus the consensus estimate of $560.59 million.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Reading (RDI) Tops Q2 EPS by 4c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery